bezafibrate has been researched along with Cholangitis, Sclerosing in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arizumi, T; Isayama, H; Nakazawa, T; Takikawa, H; Tanaka, A; Tazuma, S; Tsuyuguchi, T | 1 |
| Beuers, U; Bolier, R; de Vree, M; de Vries, E; Drenth, J; Goet, J; Helder, J; Mostafavi, N; Oude Elferink, R; Parés, A; Ponsioen, C; van Buuren, H; van der Heide, F; van Erpecum, K; van Nieuwkerk, K; Verbeek, J | 1 |
| Hasegawa, S; Honda, Y; Hosono, K; Kurita, Y; Nakajima, A; Nogami, A; Yoneda, M | 1 |
| Beuers, U; Bolier, R; de Vries, ES; Elferink, RPO; Helder, J; Kemper, EM; Parés, A; Zwinderman, K | 1 |
| Ben Belkacem, K; Chazouillères, O; Corpechot, C; Gaouar, F; Housset, C; Kemgang Fankem, AD; Lemoinne, S; Pares, A; Poupon, R; Reig, A | 1 |
| Ando, M; Harada, K; Hirohata, M; Miyake, Y; Moriya, A; Nakanuma, Y; Takemoto, R; Yamamoto, K | 1 |
| Hirano, K; Isayama, H; Koike, K; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Tada, M; Watanabe, T; Yamamoto, N | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kawabe, T; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
| Hachiya, T; Hanaoka, I; Kimura, T; Kita, R; Kita-Sasai, Y; Kokuryu, H; Osaki, Y; Shimizu, T; Takamatsu, S; Tomono, N | 1 |
| Kamatani, N; Kurihara, T; Maeda, A; Shigemoto, M; Yamashita, K | 1 |
| Gondoh, K; Imamura, K; Miyakoda, K; Mukasa, M; Ono, T; Sata, M; So, A | 1 |
| Fukuyama, T; Hachiya, T; Hatano, H; Kimura, T; Kita, R; Kokuryu, H; Komekado, H; Komibuchi, T; Maruo, T; Osaki, Y; Sawabu, T; Shimizu, T; Takamatsu, S; Tomono, N; Tsuji, K | 1 |
1 review(s) available for bezafibrate and Cholangitis, Sclerosing
| Article | Year |
|---|---|
Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents.
Topics: Anti-Bacterial Agents; Bezafibrate; Cholagogues and Choleretics; Cholangitis, Sclerosing; Fibroblast Growth Factors; Glucocorticoids; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Peroxisome Proliferator-Activated Receptors; Probiotics; Receptors, Cytoplasmic and Nuclear; Tumor Necrosis Factor-alpha | 2021 |
3 trial(s) available for bezafibrate and Cholangitis, Sclerosing
| Article | Year |
|---|---|
Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.
Topics: Adult; Bezafibrate; Cholangitis, Sclerosing; Double-Blind Method; Female; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; Placebos; Pruritus; Quality of Life; Severity of Illness Index; Treatment Outcome; Visual Analog Scale | 2021 |
Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial.
Topics: Antipruritics; Bezafibrate; Cholangitis, Sclerosing; Clinical Protocols; Double-Blind Method; Humans; Liver Cirrhosis, Biliary; Netherlands; Pruritus; Research Design; Spain; Time Factors; Treatment Outcome | 2017 |
Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis.
Topics: Administration, Oral; Adult; Aged; Bezafibrate; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis, Sclerosing; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hospitals, University; Humans; Japan; Liver Function Tests; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2015 |
8 other study(ies) available for bezafibrate and Cholangitis, Sclerosing
| Article | Year |
|---|---|
Ursodeoxycholic acid is associated with improved long-term outcome in patients with primary sclerosing cholangitis.
Topics: Bezafibrate; Cholagogues and Choleretics; Cholangitis, Sclerosing; Humans; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Ursodeoxycholic Acid | 2022 |
Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
Topics: Adult; Aged; Alkaline Phosphatase; Bezafibrate; Cholagogues and Choleretics; Cholangitis, Sclerosing; Drug Therapy, Combination; Female; Fenofibrate; France; Humans; Hypolipidemic Agents; Liver Function Tests; Male; Middle Aged; Pruritus; Retrospective Studies; Spain; Ursodeoxycholic Acid; Young Adult | 2018 |
Overlap of IgG4-related sclerosing cholangitis and primary biliary cirrhosis.
Topics: Bezafibrate; Cholagogues and Choleretics; Cholangitis, Sclerosing; Drug Therapy, Combination; Humans; Immunoglobulin G; Liver Cirrhosis, Biliary; Male; Middle Aged; Ursodeoxycholic Acid | 2014 |
Bezafibrate for the treatment of primary sclerosing cholangitis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bezafibrate; Cholangitis, Sclerosing; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Liver Function Tests; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome | 2010 |
Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports).
Topics: Adult; Aged; Bezafibrate; Cholangitis, Sclerosing; Humans; Hypolipidemic Agents; Male; Middle Aged | 2002 |
Efficacy of bezafibrate in a patient with primary sclerosing cholangitis.
Topics: Adolescent; Alkaline Phosphatase; Bezafibrate; Cholangitis, Sclerosing; Humans; Hypolipidemic Agents; Liver Function Tests; Male; Treatment Outcome | 2003 |
[Bezafibrate alone is an effective first-line therapy for primary sclerosing cholangitis: a case report].
Topics: Administration, Oral; Bezafibrate; Cholangitis, Sclerosing; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Middle Aged | 2006 |
[A case of primary sclerosing cholangitis presenting transient hypoperfusion and treated with bezafibrate beneficially].
Topics: Alkaline Phosphatase; Bezafibrate; Bile Ducts; Biomarkers; Cholangitis, Sclerosing; Drug Therapy, Combination; Humans; Ischemia; Male; Middle Aged; Treatment Outcome; Ursodeoxycholic Acid | 2002 |